AZD6088 Single Ascending Dose study
Study identifier:D0840C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD6088 after Single Ascending Doses in Healthy Male and Non-Fertile Female Volunteers
Medical condition
Healthy Volunteers
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6088, Placebo
Sex
All
Actual Enrollment
35
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jun 2009
Primary Completion Date: -
Study Completion Date: 01 Aug 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: A AZD6088 oral solution | Drug: AZD6088 Oral solution. Each subject will receive a single-dose of AZD6088. |
| Experimental: B Placebo oral solution | Drug: Placebo Oral solution. Each subject will receive a single-dose of placebo. |
Contacts
Investigators
Principal Investigator
Biljana Lilja
AstraZeneca R&D, Södertälje, Sweden
